Viatris

CompanyUnited StatesFounded 202030,000 staff

ROROpenAlexWikidata

Viatris develops 21 assets, the furthest approved (DILANTIN-125). Mostly small molecule and protein or enzyme acting on CACNA1C, CACNA1D and CACNA1S; based in the United States, founded in 2020.

21
Assets
Furthest stage
Approved
462
Trials
51
Signals

Pipeline

21
  • DILANTIN-125

    Approved

  • Lipitor

    HMG-CoA reductase inhibitor lowering circulating low-density lipoprotein cholesterol levels.

    Approved, Small molecule, HMGCR, angina pectoris, coronary artery disease

  • Lyrica

    Approved, Small molecule, CACNA1G, CACNA1H, neuropathic pain, postherpetic neuralgia

18 more assets

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

7

In the full profile

  • Evidence behind the mechanisms11
  • Trials486
  • Deals1
  • Signals20
  • Similar companies6

Papers

Intelligence